LONDON, 16 October 2006 — Dr Steve Arlington and several other industry specialists are being appointed to expand the breadth of expertise offered by the pharmaceutical and life sciences practice of PricewaterhouseCoopers member firms. These appointments form part of an ongoing drive to develop and build the group’s performance improvement capability. Their primary focus will be advising pharmaceutical and life sciences clients on a range of issues covering manufacturing, business development strategy, R&D and sales and marketing.
Dr Steve Arlington brings a wealth of experience to the team and will be working to bring innovative solutions to issues facing clients in areas including R&D effectiveness, strategy and patient compliance. He has over 15 years consulting experience, 10 years of which focused on pharma and life sciences. Steve has worked with many of the larger pharmaceutical and life science companies on R&D strategy and effectiveness and is a Fellow of the Royal Society of Medicine and a member of the Drug Information Association.
Simon Friend, global pharmaceutical leader, PricewaterhouseCoopers LLP said:
"The pharmaceutical and life sciences industry is experiencing a period of intense change in the areas of development, regulatory compliance, sales and marketing, manufacturing and drug lifecycle management. The advisory capability which we offer clients continually evolves to reflect and anticipate developments in the global pharmaceutical and life sciences industry. The addition of Steve Arlington and others to our expanding pharmaceutical and life sciences network will provide our clients with proven, field-tested solutions to improve their performance.”
Todd Evans has joined as a director in the Pharmaceutical and Life Sciences Advisory Services group with responsibility for working with pharmaceutical and life sciences industry clients on a wide range of supply chain management issues. Todd will advise clients on channel strategy and design, logistics strategy and design, strategic sourcing and purchasing, cost management, and demand planning and is located in the Chicago office.
Also joining the same team as a director is Holly Kramen. Located in the Los Angeles office, Holly will be responsible for working with pharmaceutical, biotech and life sciences industry clients on marketing and sales issues with a particular focus on enhancing compliance and productivity in these areas. Holly is an attorney and brings broad expertise in pharmaceutical marketing and sales operations and healthcare law throughout the entire product lifecycle. Her background includes experience in operational mergers and expansions, training compliance programs, and leadership, strategy, management and sales training. She specialises in providing advice on practical applications of compliance requirements affecting marketing and sales activities as well as and in analysis, design, implementation, training and documentation of supportive processes and systems.
Noreen Dowd has been appointed as a partner in the performance improvement team in Australia to focus on planning and change in the healthcare sector.
These recruitments build on key appointments during 2005 such as Sandy Johnston who joined as a director to lead the performance improvement team. Based in London he works on strategy, process and technology in the areas of R&D, commercialisation and supply chain.
ENDS
Notes to Editor:
- A photograph of Dr Steve Arlington is available from Kristina Blissett on +44 (0)20 7212 5133 or by email (listed in contact box).
- PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group (www.pwc.com/pharma) provides clients with audit, tax and advisory services. The firm has extensive experience in delivering solutions to a wide range of strategic, financial and operational issues. The firm has also developed industry-specific services in the areas of regulatory compliance, IT and financial effectiveness, and performance improvement.
- The member firms of the PricewaterhouseCoopers network (www.pwc.com) provide industry focused assurance, tax and advisory services to build public trust and enhance value for its clients and their stakeholders. More than 130,000 people in 148 countries across our network work collaboratively using connected thinking to develop fresh perspectives and practical advice.
“PricewaterhouseCoopers” refers to the network of member firms of PricewaterhouseCoopers International Limited, each of which is a separate and independent legal entity.
